安图生物
(603658)
| 流通市值：337.52亿 | | | 总市值：337.52亿 |
| 流通股本：5.86亿 | | | 总股本：5.86亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,089,195,256.05 | 4,443,655,727.69 | 3,242,497,407.54 | 2,107,941,206.59 |
| 营业收入 | 1,089,195,256.05 | 4,443,655,727.69 | 3,242,497,407.54 | 2,107,941,206.59 |
| 二、营业总成本 | 777,943,233.44 | 3,214,959,512.36 | 2,326,702,156.56 | 1,556,340,161.47 |
| 营业成本 | 386,453,063.84 | 1,552,245,154.49 | 1,148,089,595.75 | 766,336,513.88 |
| 税金及附加 | 10,900,737.72 | 50,727,338.55 | 37,883,803.48 | 24,609,344.87 |
| 销售费用 | 180,832,585.13 | 763,333,422.86 | 541,572,670.49 | 363,457,740.78 |
| 管理费用 | 46,553,519.32 | 183,734,754.8 | 134,330,968.43 | 91,440,696.51 |
| 研发费用 | 151,149,747.29 | 656,130,426.05 | 461,553,959.8 | 310,910,837.82 |
| 财务费用 | 2,053,580.14 | 8,788,415.61 | 3,271,158.61 | -414,972.39 |
| 其中:利息费用 | 6,347,252.8 | 24,541,986.54 | 17,139,727.42 | 10,754,383.88 |
| 其中:利息收入 | 5,150,017.57 | 15,381,295.46 | 12,629,958.85 | 9,903,589.47 |
| 加:公允价值变动收益 | 3,407,049.84 | 579,888.51 | - | - |
| 加:投资收益 | 22,967,999.31 | 129,381,351.61 | 82,312,144.21 | 51,748,064.48 |
| 资产处置收益 | 135.13 | -137,779.8 | -67,760.16 | -67,760.16 |
| 资产减值损失(新) | 1,374,245.66 | -32,691,713.54 | -23,131,957.44 | -21,191,248.35 |
| 信用减值损失(新) | -474,196.5 | -22,643,567.95 | -21,217,791.46 | -12,058,346.9 |
| 其他收益 | 25,457,104.09 | 62,563,558.61 | 52,788,665.57 | 35,934,900.22 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 363,984,360.14 | 1,365,747,952.77 | 1,006,478,551.7 | 605,966,654.41 |
| 加:营业外收入 | 1,544,422.67 | 3,190,228.03 | 4,890,083.23 | 4,588,600.67 |
| 减:营业外支出 | 3,716,320.19 | 6,394,267.64 | 4,645,306.72 | 1,850,114.35 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 361,812,462.62 | 1,362,543,913.16 | 1,006,723,328.21 | 608,705,140.73 |
| 减:所得税费用 | 33,112,994.33 | 138,413,224.5 | 91,312,583.04 | 53,403,660.6 |
| 六、净利润 | 328,699,468.29 | 1,224,130,688.66 | 915,410,745.17 | 555,301,480.13 |
| 持续经营净利润 | 328,699,468.29 | 1,224,130,688.66 | 915,410,745.17 | 555,301,480.13 |
| 归属于母公司股东的净利润 | 324,212,004.34 | 1,217,438,887.27 | 900,920,385.63 | 545,873,021.66 |
| 少数股东损益 | 4,487,463.95 | 6,691,801.39 | 14,490,359.54 | 9,428,458.47 |
| (一)基本每股收益 | 0.56 | 2.1 | 1.55 | 0.94 |
| (二)稀释每股收益 | 0.56 | 2.1 | 1.55 | 0.94 |
| 八、其他综合收益 | 13,321.47 | 424,846.11 | 587,541.93 | 615,993.25 |
| 归属于母公司股东的其他综合收益 | 13,321.47 | 424,846.11 | 587,541.93 | 615,993.25 |
| 九、综合收益总额 | 328,712,789.76 | 1,224,555,534.77 | 915,998,287.1 | 555,917,473.38 |
| 归属于母公司股东的综合收益总额 | 324,225,325.81 | 1,217,863,733.38 | 901,507,927.56 | 546,489,014.91 |
| 归属于少数股东的综合收益总额 | 4,487,463.95 | 6,691,801.39 | 14,490,359.54 | 9,428,458.47 |
| 公告日期 | 2024-04-19 | 2024-04-19 | 2023-10-26 | 2023-08-18 |
| 审计意见(境内) | | 标准无保留意见 | | |